Integrated Oncology Learning - Activity Details

  1. Read the Activity Overview
  2. Take the Pretest
  3. Take the Activity
  4. Take the Posttest/Evaluation
  5. View/Print CME Certificate

To begin this activity, read all of the conditions in the Activity Terms box at the bottom of this page, then click "I Accept the Terms."

View all IOL Details

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Online Grand Rounds:
Exploiting Targeted Therapies for Improved Outcomes in Renal Cell Carcinoma

0.5 AMA PRA Category 1 Credit(s)™
Release Date: July 24, 2009
Expiration Date: July 24, 2010

Lecture Overview

Targeted therapy is now the primary management option for advanced/metastatic renal cell carcinoma (RCC). Currently approved agents for advanced/metastatic RCC include antiangiogenic tyrosine kinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors. Additional agents are also in various stages of clinical investigation as first-line or later therapies. While the existence of multiple therapeutic options benefits the patient, it expands the complexity of the decision-making process and creates the need to inform oncologists of the practical differences between agents, their comparative advantages and disadvantages, and patient criteria for treatment individualization and optimization.

The purpose of this activity is to review the systemic treatment options available for advanced/metastatic RCC as well as considerations in patient selection.

Presented by Physicians’ Education Resource in conjunction with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

This educational activity is directed toward medical oncologists and other specialists practicing in the community or academic setting who are interested in the treatment of RCC. Physicians involved in the long-term management of cancer patients as well as fellows, oncology physician assistants, oncology nurses, research nurses, and others with an interest in the treatment of patients with RCC are also invited to participate.

Upon completion of this educational activity, you should be able to:

  • Evaluate the efficacy of antiangiogenic agents in advanced/metastatic RCC
  • Assess the clinical utility of mTOR inhibitors in advanced/metastatic RCC
  • Incorporate the current treatment algorithm for advanced/metastatic RCC based on patient risk, treatment history, and evidence from clinical trials into formulating treatment decisions for individual patients

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. View the Flash video presentation and slides.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

Complete the test(s) and evaluation by July 24, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

Steven T. Rosen, MD, FACP
Research Funding – Berlex Oncology, Celgene Corporation, Wyeth Pharmaceuticals
Paid Consultant – Abbott Laboratories; Allos Therapeutics, Inc.; Berlex Oncology; Biocryst Pharmaceuticals, Inc.; Celgene Corporation; CT International; Eli Lilly and Company; Genentech, Inc.; Genta Incorporated; Ligand Pharmaceuticals, Inc.; Pharmion Corporation; Sigma-tau Pharmaceuticals, Inc.; SuperGen; THERAKOS, Inc.; Wyeth Pharmaceuticals
Speaker’s Bureau – Merck & Co., Inc.
Other Remuneration – Celgene Corporation; Genentech, Inc.; Ligand Pharmaceuticals, Inc.

Gary R. MacVicar, MD
No relevant relationships to disclose

PER Editorial Staff
No relevant relationships to disclose

This CME activity includes discussion of investigational and/or unlabeled uses of drugs, including the use of axitinib; pazopanib; VEGF Trap (aflibercept); bevacizumab in combination with interferon alfa, everolimus, temsirolimus, or sorafenib; and temsirolimus in combination with sorafenib in advanced renal cell carcinoma. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Commercial Support

Educational grants for this activity were provided by Genentech BioOncology and Novartis Oncology.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Additional software requirements include:

Macintosh Users
Compatible Web browsers include:

Additional software requirements include:

Disclaimer

The views and opinions expressed in this learning activity are those of the presenters and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenters and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2009 by Physicians’ Education Resource.

All correspondence should be directed to:
Editor, Exploiting Targeted Therapies for Improved Outcomes in Renal Cell Carcinoma
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

140-8640_01

Educational Grants

An educational grant for this activity was provided by:


  1. Genentech BioOncology
  2. Novartis Oncology